Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS

[1]  G. Phillips,et al.  Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia , 2010, British journal of haematology.

[2]  L. Rybicki,et al.  Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non‐Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide , 2010, British journal of haematology.

[3]  L. Nguyen,et al.  Exposure equivalence between IV (0.8 mg/kg) and oral (1 mg/kg) busulfan in adult patients , 2009, European Journal of Clinical Pharmacology.

[4]  L. Rybicki,et al.  A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation , 2004, Bone Marrow Transplantation.

[5]  J. Radich,et al.  HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. , 2003, Blood.

[6]  J. Niland,et al.  Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  H. Deeg,et al.  Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. , 2002, Blood.

[8]  J. Wingard,et al.  Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  F. Spijkervet,et al.  Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Labopin,et al.  A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia , 1996, British journal of haematology.

[11]  J. Klein,et al.  Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. , 1991, Blood.

[12]  L. Grochow,et al.  Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. , 1987, Cancer research.

[13]  R. Brookmeyer,et al.  Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. , 1983, The New England journal of medicine.

[14]  P. Neiman,et al.  One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. , 1977, Blood.

[15]  L. Nguyen,et al.  Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study , 2005, Cancer Chemotherapy and Pharmacology.

[16]  L. Grochow,et al.  A clinician's guide to chemotherapy pharmacokinetics and pharmacodynamics , 1998 .